Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children

J Infect Dis. 2002 May 15;185(10):1409-16. doi: 10.1086/340614. Epub 2002 Apr 30.

Abstract

Human immunodeficiency virus (HIV) type 1 DNA in peripheral blood mononuclear cells (PBMC) was quantified in 31 children who received efavirenz, nelfinavir, and 1 or 2 nucleoside reverse-transcriptase inhibitors for > or =2 years and in whom undetectable plasma HIV-1 RNA levels (< 50 copies/mL) were sustained, to determine the usefulness of HIV-1 DNA as a marker of virus suppression. The median baseline HIV-1 DNA level was 750 copies/10(6) PBMC. After initiation of highly active antiretroviral therapy (HAART), HIV-1 DNA levels decreased gradually, reaching a plateau from week 80 through week 104 (median HIV-1 DNA level, 263 copies/10(6) PBMC). Children who had plasma HIV-1 RNA levels < 50 copies/mL after receiving HAART for 8 weeks (n=16) had persistently lower quantities of intracellular HIV-1 DNA than children whose HIV-1 RNA levels reached < 50 copies/mL after 8 weeks of HAART (n=15). The median half-life for intracellular HIV-1 DNA was 60 weeks. Thus, despite prolonged maintenance of undetectable levels of plasma HIV-1 RNA, HIV-1 DNA remains detectable in PBMC of children and may be a useful marker of further virus suppression.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Alkynes
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • Benzoxazines
  • Biomarkers / analysis
  • Biomarkers / blood
  • Child
  • Child, Preschool
  • Cyclopropanes
  • DNA, Viral / analysis*
  • DNA, Viral / blood
  • Drug Therapy, Combination
  • Female
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV Protease Inhibitors / therapeutic use
  • HIV-1 / isolation & purification*
  • Half-Life
  • Humans
  • Infant
  • Leukocytes, Mononuclear / virology*
  • Male
  • Nelfinavir / therapeutic use
  • Oxazines / therapeutic use
  • RNA, Viral / blood*
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Viral Load

Substances

  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Biomarkers
  • Cyclopropanes
  • DNA, Viral
  • HIV Protease Inhibitors
  • Oxazines
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • Nelfinavir
  • efavirenz